Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more

Conditions: Androgenetic Alopecia, Hair Loss, Thinning Hair, Balding
Interventions: Genix, Sham; Device
Lead sponsor: Kiierr International, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Mendham, New Jersey

Conditions: Thrombocytopaenia
Interventions: Eltrombopag, Azacitidine, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Total Knee Arthroplasty
Interventions: Oxycodone, Placebo Oral Tablet; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 89 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Secondhand Smoke, Air Trapping, Tobacco, Airflow Limitation, Hyperinflation, Obstructive Lung Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 80 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 4
States / cities: Cullman, Alabama • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: Hypertension, End Stage Renal Disease
Interventions: Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lumbar Disc Disease, Spinal Fusion, Degenerative Disc Disease
Interventions: Propranolol Hcl 40mg Tab, Placebo oral tablet; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Heart Failure
Interventions: LCZ696, valsartan, LCZ696 placebo, valsartan placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Beverly Hills, California • Sacramento, California • San Diego, California + 28 more

Conditions: Septic Shock
Interventions: hydrocortisone, Normal Saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, Escitalopram; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Orlando, Florida • Prairie Village, Kansas • Allentown, Pennsylvania + 1 more

Conditions: Apnea of Prematurity
Interventions: Caffeine, Sterile Water Placebo; Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 1 Week to 40 Weeks
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Spinocerebellar Ataxia Type 3
Interventions: SLS-005, Placebo; Drug
Lead sponsor: Seelos Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more

Conditions: Healthy
Interventions: HIP2B, Placebo; Drug
Lead sponsor: CureDM; Industry
Eligibility: 19 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pirfenidone, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions: Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate; Procedure · Drug · Combination Product
Lead sponsor: Gary Van Guilder; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Gunnison, Colorado

Conditions: Myasthenia Gravis, Generalized
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 58
States / cities: Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions: Mitapivat, Mitapivat-matching placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 6 more

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone Bromide, Placebo-Normal Saline; Drug
Lead sponsor: St. John Health System, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: IVIG, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 2,416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 1991
U.S. locations: 8
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more

Conditions: Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions: Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%; Drug
Lead sponsor: Waihong Chung; Other
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Search by objective public record fields.

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Low Level Light Device as a Primary Therapy for Androgenetic Alopecia

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

Secondhand Smoke Respiratory Health Study

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock

A Study for Participants With Major Depression

Caffeine Use in the Management of Preterm Infants

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Effect of Testosterone in Men With Erectile Dysfunction

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy